Clinical whole genome sequencing as a first-tier test at a resource-limited dysmorphology clinic in Mexico
Clinical whole genome sequencing as a first-tier test at a resource-limited dysmorphology clinic in Mexico
AbstractPatients with rare, undiagnosed, or genetic disease (RUGD) often undergo years of serial testing, commonly referred to as the “diagnostic odyssey”. Patients in resource-limited areas face even greater challenges—a definitive diagnosis may never be reached due to difficulties in gaining access to clinicians, appropriate specialists, and diagnostic testing. Here, we report on a collaboration of the Illumina iHope Program with the Foundation for the Children of the Californias and Hospital Infantil de Las Californias, to enable deployment of clinical whole genome sequencing (cWGS) as first-tier test in a resource-limited dysmorphology clinic in northern Mexico. A total of 60 probands who were followed for a suspected genetic diagnosis and clinically unresolved after expert examination were tested with cWGS, and the ordering clinicians completed a semi-structured survey to investigate change in clinical management resulting from cWGS findings. Clinically significant genomic findings were identified in 68.3% (n = 41) of probands. No recurrent molecular diagnoses were observed. Copy number variants or gross chromosomal abnormalities accounted for 48.8% (n = 20) of the diagnosed cases, including a mosaic trisomy and suspected derivative chromosomes. A qualitative assessment of clinical management revealed 48.8% (n = 20) of those diagnosed had a change in clinical course based on their cWGS results, despite resource limitations. These data suggest that a cWGS first-tier testing approach can benefit patients with suspected genetic disorders.
- University of California, San Francisco United States
- Illumina (United Kingdom) United Kingdom
- Illumina (Singapore) Singapore
- King Abdulaziz University
- ILLUMINA, INC.
Pediatric, screening and diagnosis, Human Genome, ICSL Interpretation and Reporting Team, 610, Article, 4.1 Discovery and preclinical testing of markers and technologies, Detection, Good Health and Well Being, Clinical Research, 616, Genetics, Genetic Testing, 4.2 Evaluation of markers and technologies
Pediatric, screening and diagnosis, Human Genome, ICSL Interpretation and Reporting Team, 610, Article, 4.1 Discovery and preclinical testing of markers and technologies, Detection, Good Health and Well Being, Clinical Research, 616, Genetics, Genetic Testing, 4.2 Evaluation of markers and technologies
15 Research products, page 1 of 2
- 2003IsRelatedTo
- 2019IsRelatedTo
- 2007IsRelatedTo
- 2020IsRelatedTo
- 2020IsRelatedTo
- 2003IsRelatedTo
- 2020IsRelatedTo
- 2020IsRelatedTo
chevron_left - 1
- 2
chevron_right
citations This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).73 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Top 1% influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Top 10% impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Top 1%
